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Abstract
Background: Gestational diabetes mellitus (GDM) is common during pregnancy. This survey was
designed based on the frequency of GDM among an urban population according to the American
Diabetes Association (ADA) and the International Association of Diabetes and Pregnancy Study
Groups (IADPSG) criteria.
Methods: We included all pregnant women who were admitted to a gynecology clinic from Sep-
tember 2012 until May 2013. The fasting blood sugar (FBS) was measured. Those having FBS≥ 126
mg/dl were excluded from the study. All women underwent a standard OGTT (oral glucose tolerance
test) by ingesting 75g of glucose in the 24th to 32nd week of their pregnancy.
Results: Two hundred ninety pregnant women with a mean±SD age of 27.72±5.091 years were
included in the study. The mean±SD FBS, blood glucose one hour and two hours after ingesting 75g
of glucose were 82.48±9.41, 146.86±34.22 and 114.21±27.79 mg/ dl, respectively. Based on the cri-
teria of the ADA, 9.3% (n= 27) of the admitted patients suffered from GDM. For the IADPSG and
the WHO, those numbers were 31% (n= 90) and 15.2% (n= 44), respectively.
Conclusion: The prevalence of GDM was 1.5-times and 3 times higher when the IADPSG based
data were compared to those of the WHO or the ADA.
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Introduction
Gestational diabetes mellitus (GDM) is
defined as any stage of hyperglycemia
which is first expressed or diagnosed dur-
ing pregnancy. GDM is the most prevalent
disorder during pregnancy, resulting in dis-
ability and perinatal complications as well
as neonatal problems (1-3).
The prevalence of this condition differs
vastly among countries (4). The occurrence
of GDM is also expected to increase in up-
coming years; its prevalence in the USA
and Turkey is calculated to be 7% and
4.48%, respectively (5-7).  In Iran, the
numbers vary between provinces from
1.3% to 8.9% (8). In 2011, Mexico reported
the prevalence of GDM to be 10.3% ac-
cording to the ADA index (30.1% using the
IADPSG criteria) (9).
As well as being highly prevalent, GDM
can be considered a predisposing factor for
type 2 diabetes. Thus, any attempt to diag-
nose GDM earlier seems critical (10,11).
In 1997, the American Diabetes Associa-
tion (ADA) proposed indexes for the diag-
nosis of GDM in the 24th week of pregnan-
cy (1). The comprehensive research known
as HAPO (Hyperglycemia and Adverse
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9 countries showed that even in mothers
with normal plasma glucose values (ac-
cording to the ADA index), there is still a
strong correlation between diabetes com-
plications and plasma glucose levels. The
findings of this research were interpreted,
and in 2011 the International Association of
Diabetes and Pregnancy Study Groups
(IADPSG) introduced new criteria for the
diagnosis of GDM which seem to be more
sensitive (12). Although the ADA supports
and recommends its use, the new criteria
are not yet widely used by doctors (13).
The HAPO project results showed that for
every 6.9 mg/dl increase in the blood glu-
cose, the chance of complications from
GDM, such as macrosomia, cord-blood se-
rum C-peptide levels and primary cesarean
delivery, multiplies by 1.38, 1.55, and 1.1
times, respectively. This research also con-
cluded that the existing criteria do not pre-
dict the complications of diabetes suffi-
ciently (7,12).
Taking into the account the high preva-
lence of GDM in Iran, this survey was de-
signed to calculate the frequency of this
disease among urban populations according
to the ADA and IADPSG criteria.
Methods
We included all pregnant women who
were admitted to the gynecology wards of
Rafsanjan hospitals from September 2012
until March 2013. After their first gyneco-
logical examination, the participants signed
written informed consent forms for partici-
pation in the study. This study was ap-
proved by the Ethics Committee of Tehran
University of Medical Sciences.
The fasting blood sugar (FBS) was meas-
ured after the first visit. Those having FBS
≥ 126 mg/dl were assumed to have appar-
ent diabetes mellitus and were excluded
from the study. Other exclusion criteria
were a history of gestational diabetes, thy-
roid, liver, heart or renal dysfunction and a
history of consuming any kind of cortico-
steroids. Standard oral glucose tolerance
test (OGTT) was done by ingesting 75g of
glucose in the 24th to 32nd week of preg-
nancy. If the patient was admitted to the
ward after her 24th week of pregnancy, her
FBS level was read from her hospital doc-
ument and then OGTT was performed. All
of the tests were done in a single laborato-
ry. All data were recorded on a checklist.
Data were analyzed using SPSS 20 and
were reported as average, standard devia-
tion and percentages. T-test was used to
compare the quantitative indexes. Chi
square was used to compare the categorical
variables between different criteria. Lo-
gistic regression tests were done to evaluate
the correlation between different variables
with the diagnosis of GDM.  P value<0.05
was considered as statistically significant.
Results
Two hundred ninety pregnant women
with the average age of 27.72±5.091 years
in age 1.91±1.02 gravidity (from 1 to 6,
with a median of 2), and 0.73±0.84 parity
(from 0 to 4 with a median of 1) were in-
cluded in the study.
The mean±SD of BMI at the time of en-
rolment was 27.62±4.58 and the mean±SD
of systolic and diastolic pressures were
109.11±12.27 and 63.65±6.57 mmHg, re-
spectively. Family history of diabetes type
2 was present in 31% of the participants



















Age 27.6± 5 29.1±5.7 0.100 27.3±4.9 28.6±5.3 0.050 27.4±4.9 29.4±5.7
BMI 27.5±4.6 28.8±3.9 0.100 26.9±4.3 29.1±4.7 <0.001 27.4±4.7 28.7±3.4
Parity 0.7±0.8 0.9±1 0.100 0.7±0.7 0.8±0.9 0.100 0.7±0.8 0.9±1
Gravid 1.9±1 2.2±1.1 0.100 1.9±1 1.9±1 0.100 1.9±1 2.1±1
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(n= 90). From the patients with at least one
delivery (n= 155), 1.9% and 2.5% had a
history of GDM and delivery of macrosom-
ic infant respectively. Fifteen percent of the
participants (n= 43) had FBS≥ 92mg/dl.
The mean±SD FBS, blood glucose one
hour, and two hours after ingesting 75 g of
glucose were 82.48±9.41, 146.86±34.22,
and 114.21±27.79mg/dl, respectively.
Based on the criteria of the ADA, 9.3% (n
= 27) of the admitted patients suffered from
GDM. For the IADPSG and the WHO,
those numbers were 31% (n= 90) and
15.2% (n= 44), respectively. Tables 1 and 2
demonstrate the correlation between GDM
and known pregnancy risk factors.
In the regression analysis, according to
the new criteria, blood sugar did not regress
with either gravidity (p= 0.99), parity (p=
0.27), or age of pregnancy (p= 0.87). How-
ever, in the logistic regression, the only
significant variable was the patient’s histo-
ry of type 2 diabetes (p= 0.009, OR= 2.02
(95% CI: 1.19-3.44)).
Discussion
This study compared ADA and IADPSG
criterion in a sample of pregnant women
from Rafsanjan in 2012 and 2013. We cal-
culated the prevalence of GDM to be 9.3%,
15.2%, and 31%, respectively based on the
ADA, IADPSG and WHO criteria. As re-
ported in other studies, lowering GDM’s
diagnosis cut-off resulted in a higher preva-
lence (The ADA had the highest cut-off
and thus the least prevalence). The preva-
lence of GDM was 1.5 times and 3 times
higher based on the IADPSG criteria than
based on the WHO and ADA criterion. It is
quite obvious that having a less expensive
and more sensitive screening test would
produce the best desired result. As in
IADPSG and ADA, 3 and 4 blood sugar
assessments are required. Although their
diagnostic cut-offs are different, all patients
reported to have GDM by IADPSG criteria
had the same results as ADA; therefore, it
seems that using IADPSG is more reasona-
ble. Whether this triple increase in GDM
prevalence is in line with any change in
mother and neonatal complications after
pregnancy, needs to be determined in future
studies.
Similar studies had been done in various
countries. For example, in Japan, the preva-
lence of GDM was reported to be 2.4% and
6.6%, using previous and new criteria, re-
spectively. The prevalence of macrosomia
was found to be significantly different in
normal patients based on the ADA criteria
compared to a similar group using IADPSG
indexes. The researchers concluded that
using the new method would increase the
cases of GDM at least 2.7 times (14).
In another study done in Ireland, the
prevalence of GDM changed from 9.4% to
12.4% using the IADPSG instead of the
WHO criteria (15). In a similar study con-
ducted in the UAE, the prevalence of GDM
was reported to be 12.9% according to the
ADA and 37.7% according to the IADPSG.
It was concluded that lowering the cut-off
of two-hour glucose blood according to the
IADPSG was the reason for the increase in
GDM prevalence, making it the most im-
portant index (16).In contrast with the re-
sults of previous studies, our work showed
that the number of positive cases of the



















Preeclampcy 0 (0) 1(0.34) 0.09 0(0) 1(0.34) 0.30 0(0) 1(0.34)
Hx of macrosomic infant 0(0) 4(1.37) 0.50 1(0.34) 3(1) 0.70 0(0) 4(1.37)
Hx of GDM 1(0.34)) 2(0.69) 0.02 0(0) 3(1) 0.02 1(0.34) 2(0.69)
FHx of DM 77(26.5) 10(3.5) 0.40 50(17.2) 37(12.7) 0.01 17(5.9) 7024)
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FBS test, 1h OGTT, and 2h OGTT were
52, 48, and 24, respectively. Moreover, 43
patients had an FBS value of more than 92
mg/dl prior to OGTT, which is half the
number of GDM cases. These findings
show that the sensitivity of the FBS test
seems to be high. On the other hand, in our
study, the correlation between diabetes and
a woman’s BMI, a history of diabetes in the
family and age were significant. Based on
these findings and the fact that the treat-
ment of choice for GDM is a modified diet,
the cost effectiveness of GDM screening is
more reasonable. One of our limitations in
this study was the absence of BMI score
documentation before pregnancy. We con-
sidered the BMI of the patients during
pregnancy an independent variable; thus,
our interpretations could be false.
Conclusion
This study was designed to compare the
prevalence of GDM with respect to differ-
ent criteria. According to the ADA, the
WHO, and the IADPSG, the prevalence of
GDM was calculated to be 8%, 15.1% and
21%, respectively. The prevalence of GDM
was 1.5-times and 3 times higher when the
IADPSG based data was compared with
those of the WHO or the ADA.
As a final point, we suggest that GDM
screening be done using IADPSG criteria.
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